Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

A high burden of heart valve diseases is driving its expansion. India’s transcatheter aortic valve replacement (TAVR) market ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

While the TAVR market is maturing, it is still far from saturated, as recent clinical trial results demonstrated. Many aortic stenosis patients prior to seeking TAVR treatment exhibit adverse ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

GlobalData’s latest report reveals that India accounted for only around 3 per cent of the market in APAC in 2024, due to ...

ACURATE neo2 TAVI achieves high success in severe bicuspid aortic stenosis, demonstrating strong 30-day safety and efficacy.

Coronary events after TAVR are rare but impact survival. PCI improves outcomes, particularly in balloon-expandable valve ...

med.ulaval.ca To be aware of the prevalence, pathophysiology and outcomes of mixed aortic valve disease (MAVD), which refers to combined aortic stenosis and aortic ... analyses in the field of ...